Uzman Dr. Sezer SAĞLAM

Yayın Ağı

Makaleler 11

1. Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+rectal cancer: Istanbul R-02 phase II randomized study

Senyurek S., Saglam S., Saglam E. K., Yanar H., Gok K., TAŞTEKİN D., et al.

ONCOLOGY RESEARCH , cilt.31, sa.5, ss.689-696, 2023 (SCI-Expanded)

2. Robotic vs. laparoscopic intersphincteric resection for low rectal cancer: a case matched study reporting a median of 7-year long-term oncological and functional outcomes

Aliyev V., Piozzi G. N., Bulut A., GÜVEN K., Bakir B., Saglam S., et al.

UPDATES IN SURGERY , cilt.74, sa.6, ss.1851-1860, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

3. IS CHROMOSOMAL RADIOSENSITIVITY A PREDICTIVE TOOL FOR CANCER RISKS?

Kolusayın Ozar M. Ö., Orta T., Dizdar Y., Saglam E. K., Saglam S., Turna A., et al.

FRESENIUS ENVIRONMENTAL BULLETIN , cilt.30, ss.4486-4498, 2021 (SCI-Expanded)

4. Y⁹⁰ selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?

Yilmaz E., Engin M. N., Oezkan Z. G., Kovan B., Bueyuekkaya F., Poyanli A., et al.

NUCLEAR MEDICINE COMMUNICATIONS , sa.12, ss.1242-1249, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

5. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

Disel U., Kose F., Bilici A., Ozguroglu M., Saglam S., Seker M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded)

6. Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase. study

GÜRAL Z., Saglam S., YÜCEL S., Kaytan-Saglam E., Asoglu O., Ordu C., et al.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY , cilt.10, sa.1, ss.40-47, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

7. Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.

Saglam S., Hacisahinogullari H., Ozturk N., Kapran Y., Gulluoglu M., Turkmen C., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.20, sa.5, ss.1201-5, 2015 (SCI-Expanded)

8. A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma

Saglam S., Aykan N. F., ŞAKAR B., GÜLLÜOĞLU M., Balik E., Karanlik H.

JOURNAL OF GASTROINTESTINAL ONCOLOGY , cilt.2, sa.1, ss.19-26, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

9. Fat Containing HCC: Findings on CT and MRI Including Serial Contrast-Enhanced Imaging

Balci N. C., Befeler A. S., Bieneman B. K., Fattahi R., Saglam S., Havlioglu N.

ACADEMIC RADIOLOGY , cilt.16, sa.8, ss.963-968, 2009 (SCI-Expanded)

10. Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients

Saglam S., Suzme R., Gurdol F.

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS , cilt.24, sa.3, ss.142-146, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

11. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas

Basaran M., Bavbek E. S., Saglam S., Eralp L., Sakar B., Atalar A. C., et al.

ONCOLOGY , cilt.72, ss.255-260, 2007 (SCI-Expanded)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 3

1. Chronomodulated Administration of Oxaliplatin plus Capecitabine (XELOX) as First Line Chemotherapy in Metastatic Colorectal Cancer Patients: Phase II Brunch Regimen Study.

Pilanci K. N., Saglam S., Okyar A., Yucel S., Kara Z. P., Ordu C., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

2. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)

Keskin S., Sen F., AYDOGAN F., Ekenel M., Kilic L., SAGLAM S., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

3. Chemoradiotherapy in the adjuvant treatment of gastric cancer

Saglam E. K., Ozturk B., Baskaya S., Saglam S., Sakar B., Yamaner S., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.315-316, (Özet Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler